{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:51:57Z","timestamp":1792266717740,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jdcr.2026.07.020","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:38:47Z","timestamp":1784389127000},"page":"271-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment of immunotherapy-associated pruritus and prurigo nodularis refractory to dupilumab with nemolizumab"],"prefix":"10.1016","volume":"75","author":[{"given":"Angela J.","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kashaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2026.07.020_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2026.101128","article-title":"Rapid reduction of immune checkpoint inhibitor\u2013associated pruritus with nemolizumab","volume":"4","author":"Kreft","year":"2026","journal-title":"EJC Skin Cancer"},{"issue":"3","key":"10.1016\/j.jdcr.2026.07.020_bib2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/bjd\/ljaf166","article-title":"Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis","volume":"193","author":"Drucker","year":"2025","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2026.07.020_bib3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jid.2023.12.003","article-title":"Comparing the efficacy of updated treatment choices for prurigo nodularis: a network meta-aAnalysis","volume":"144","author":"Wang","year":"2024","journal-title":"J Invest Dermatol"},{"issue":"13","key":"10.1016\/j.jdcr.2026.07.020_bib4","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/1078-0432.CCR-23-3431","article-title":"Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways","volume":"30","author":"Lacouture","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jdcr.2026.07.020_bib5","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/biomedicines12081886","article-title":"Review of T helper 2-type inflammatory diseases following immune checkpoint inhibitor treatment","volume":"12","author":"Mima","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.jdcr.2026.07.020_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15115","article-title":"IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice","volume":"33","author":"Kawai","year":"2024","journal-title":"Exp Dermatol"},{"issue":"17","key":"10.1016\/j.jdcr.2026.07.020_bib7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jdcr.2026.07.020_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010638","article-title":"Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events","volume":"13","author":"Khattab","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jdcr.2026.07.020_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/biomedicines9010002","article-title":"The impact of immunological checkpoint inhibitors and targeted therapy on chronic pruritus in cancer patients","volume":"9","author":"Allegra","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.jdcr.2026.07.020_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jdcr.2025.08.025","article-title":"Immune checkpoint inhibitor-associated acquired reactive perforating collagenosis treated with dupilumab","volume":"65","author":"Gold","year":"2025","journal-title":"JAAD Case Rep"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:38:03Z","timestamp":1792265883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626004388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"alternative-id":["S2352512626004388"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.07.020","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of immunotherapy-associated pruritus and prurigo nodularis refractory to dupilumab with nemolizumab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}